These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29692690)

  • 1. Overactive Bladder Syndrome: Evaluation and Management.
    Leron E; Weintraub AY; Mastrolia SA; Schwarzman P
    Curr Urol; 2018 Mar; 11(3):117-125. PubMed ID: 29692690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of overactive bladder and nocturia as a risk factor for hip fracture in climacteric women: a matched pair case control study.
    Karabulut A; Simavlı S; Demirtaş Ö; Ök N; Güngör HR; Zümrütbaş A
    J Obstet Gynaecol; 2018 Feb; 38(2):252-256. PubMed ID: 28903631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome.
    Kaufman MR; Chang-Kit L; Raj SR; Black BK; Milam DF; Reynolds WS; Biaggioni I; Robertson D; Dmochowski RR
    Neurourol Urodyn; 2017 Mar; 36(3):610-613. PubMed ID: 26859225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactive bladder treatments in early phase clinical trials.
    Colli E; Digesu GA; Olivieri L
    Expert Opin Investig Drugs; 2007 Jul; 16(7):999-1007. PubMed ID: 17594185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.
    Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C
    BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The causes and consequences of overactive bladder.
    Miller J; Hoffman E
    J Womens Health (Larchmt); 2006 Apr; 15(3):251-60. PubMed ID: 16620184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Screening test for overactive bladder in a newly developed comprehensive geriatric assessment initiative].
    Sakai M; Akai T; Takata Y; Shimizu S; Koyama S; Iwamoto T
    Nihon Ronen Igakkai Zasshi; 2013; 50(2):249-57. PubMed ID: 23979249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
    Nik-Ahd F; Lenore Ackerman A; Anger J
    Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictors of overactive bladder in nonpregnant nulliparous women below 65 years of age.
    Robinson D; Åkervall S; Wagg A; Chapple C; Milsom I; Gyhagen M
    Int Urogynecol J; 2018 Apr; 29(4):531-537. PubMed ID: 28779415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical points in the medical treatment of overactive bladder and nocturia in the elderly.
    Chen JL; Chen SF; Jiang YH; Kuo HC
    Tzu Chi Med J; 2016; 28(1):1-5. PubMed ID: 28757708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.